<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531167</url>
  </required_header>
  <id_info>
    <org_study_id>CRT 111098</org_study_id>
    <nct_id>NCT00531167</nct_id>
  </id_info>
  <brief_title>Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B</brief_title>
  <official_title>Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiviral resistance mutations limit the efficacy of therapy for chronic hepatitis B. At year
      2, resistance to adefovir may occur as high as 25% in patients with history of lamivudine
      resistance. Resistance to entecavir is reported to be 10% in lamivudine refractory patients
      during the same period. However, combination of lamivudine and adefovir decreased the
      adefovir resistance rate as low as 0% in the recent studies. By overcoming the antiviral
      resistance, the efficacy of therapy will be maximized. This study is intended to compare the
      efficacy of two strategies, combination of lamivudine and adefovir vs. entecavir monotherapy
      in patients with lamivudine resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, published data showed combination of lamivudine and adefovir lead to PCR negativity
      (&lt;1000 copies/mL) up to 80% in the treatment of lamivudine-resistant chronic hepatitis B at
      year 2 [Rapti et al. Hepatology 2007 Feb;45(2):307-13.]. Other studies also showed 76% and
      69% PCR negativity in mostly HBeAg negative subjects [Lampertico et al. Hepatology 2006
      Oct;44(4) Suppl 1:556A-557A, Lampertico et al. Hepatology 2006 Oct;44(4) Suppl 1:693A-694A].

      In the study for the treatment of lamivudine-resistant chronic hepatitis B patients which
      included HBeAg positive subjects more predominantly, entecavir monotherapy showed 34% of PCR
      negativity (&lt;300 copies/mL) at year 2 [Tenney DJ, et al. Antimicrob Agents Chemother. 2007
      Mar;51(3):902-11].

      Although it is assumed that combination of lamivudine and adefovir would be more effective
      than entecavir monotherapy for lamivudine resistant patients, we cannot verify the
      assumption, because there is no data directly comparing these two strategies until now.

      The aim of this study is to determine the most effective therapy for the patients with
      lamivudine resistant chronic hepatitis B. We will compare the PCR negativity (&lt;60 IU/ml) of
      HBV DNA at year 2 in patients receiving 'the combination of lamivudine and adefovir' and
      'entecavir monotherapy'.

      Since we are planning to include lamivudine-resistant chronic hepatitis B patients regardless
      of HBeAg status, we assumed the PCR negativity (&lt;300 copies/mL or &lt;60 IU/mL) in
      adefovir-lamivudine combination and entecavir monotherapy group as 55% and 34%, respectively,
      considering HBeAg status and lower detection limit of PCR.

      The result of this study will be able to clearly demonstrate the superiority of combination
      therapy with lamivudine and adefovir to entecavir monotherapy, which provide us the guide to
      rescue therapy for patients with lamivudine resistant HBV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR negativity (&lt;60 IU/ml) of HBV DNA</measure>
    <time_frame>At the end of year 2 (since starting rescue therapy for lamivudine resistance)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. PCR negativity (&lt;60 IU/ml) of HBV DNA at year 1 (interim analysis) 2. Degrees of HBV DNA reduction 3. ALT normalization 4. HBeAg seroconversion 5. Development of resistant mutation 6. Virologic breakthrough 7. Biochemical breakthrough</measure>
    <time_frame>At the end of year 2 except interim analysis</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>entecavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination of lamivudine+adefovir vs entecavir</intervention_name>
    <description>Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Zeffix, Hepsera, Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic hepatitis B patients (positive HBsAg &gt; 6 months)

          2. Age &gt; 16 year old

          3. Serum alanine aminotransferase (ALT) &gt;1.5 x ULN

          4. History of treatment with lamivudine more than 6 months

          5. Proven lamivudine resistant mutation

          6. HBV DNA level&gt; 20000 IU/mL

          7. Compensated liver disease (Child-Pugh-Turcotte score over 7; prothrombin time
             prolonged more than 3 sec above ULN or INR over 1.5; serum albumin &gt;3 g/dL; total
             bilirubin &lt;2.5 mg/dL; No history of variceal bleeding, ascites, or hepatic
             encephalopathy)

          8. Patients willing to give informed consent

        Exclusion Criteria:

          1. Out of inclusion criteria

          2. Any one of following

               -  Serum phosphorus level under 2.4 mg/dL

               -  Serum creatinine level over 1.5 mg/dL or creatinine clearance &lt;50 mL/min

               -  Absolute neutrophil count lower than 1000 cell/mL

               -  Hb level under 10 g/dL (male), under 9 g/dL (female)

               -  Serum AFP &gt;100 ng/mL

          3. History of treatment with interferon-a, thymosin-alfa 1, or nucleos(t)ide analogue
             other than lamivudine in 6 months of screening

          4. Recipient of organ transplantation

          5. Positive antibody test to HIV, HCV or HDV

          6. Pregnant or breast feeding women

          7. Patients with hepatocellular carcinoma or uncontrolled malignant disease

          8. Habitual alcohol drinker (&gt;140 g/week for men, &gt;70 g/week for women)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung Joon Yim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eileen Yoon</last_name>
    <role>Study Director</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeon Seok Seo, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soon Ho Um, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Wook Kim, M.D</last_name>
    <role>Study Director</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Don Lee</last_name>
    <role>Study Director</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Hoon Park, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Hallym University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung Seok Lee, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Hallym University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choong Kee Park, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Hallym University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hee Bok Chae, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Chungbuk National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moon young Kim, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soon Koo Baik, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ju Hyun Kim, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yun Soo Kim, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Il Lee, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Inha University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Woo Lee, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Inha University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sun Pyo Hong, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Genematrix Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb;45(2):507-39. Erratum in: Hepatology. 2007 Jun;45(6):1347.</citation>
    <PMID>17256718</PMID>
  </reference>
  <reference>
    <citation>Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007 Feb;45(2):307-13.</citation>
    <PMID>17256746</PMID>
  </reference>
  <reference>
    <citation>Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007 Mar;51(3):902-11. Epub 2006 Dec 18.</citation>
    <PMID>17178796</PMID>
  </reference>
  <reference>
    <citation>Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004 Jan;126(1):91-101.</citation>
    <PMID>14699491</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>lamivudine resistant mutations</keyword>
  <keyword>rescue therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 3, 2013</submitted>
    <returned>April 17, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

